학술논문
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Document Type
Article
Author
Source
In The Lancet Infectious Diseases January 2012 12(1):27-35
Subject
Language
ISSN
1473-3099